These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

264 related items for PubMed ID: 15944869

  • 1. Paradoxical effect of sibutramine on autonomic cardiovascular regulation in obese hypertensive patients--sibutramine and blood pressure.
    Birkenfeld AL, Schroeder C, Pischon T, Tank J, Luft FC, Sharma AM, Jordan J.
    Clin Auton Res; 2005 Jun; 15(3):200-6. PubMed ID: 15944869
    [Abstract] [Full Text] [Related]

  • 2. Paradoxical effect of sibutramine on autonomic cardiovascular regulation.
    Birkenfeld AL, Schroeder C, Boschmann M, Tank J, Franke G, Luft FC, Biaggioni I, Sharma AM, Jordan J.
    Circulation; 2002 Nov 05; 106(19):2459-65. PubMed ID: 12417543
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
    Sramek JJ, Leibowitz MT, Weinstein SP, Rowe ED, Mendel CM, Levy B, McMahon FG, Mullican WS, Toth PD, Cutler NR.
    J Hum Hypertens; 2002 Jan 05; 16(1):13-9. PubMed ID: 11840225
    [Abstract] [Full Text] [Related]

  • 4. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
    McMahon FG, Weinstein SP, Rowe E, Ernst KR, Johnson F, Fujioka K, Sibutramine in Hypertensives Clinical Study Group.
    J Hum Hypertens; 2002 Jan 05; 16(1):5-11. PubMed ID: 11840224
    [Abstract] [Full Text] [Related]

  • 5. Influence of sibutramine treatment on sympathetic vasomotor tone in obese subjects.
    Heusser K, Tank J, Diedrich A, Engeli S, Klaua S, Krüger N, Strauss A, Stoffels G, Luft FC, Jordan J.
    Clin Pharmacol Ther; 2006 May 05; 79(5):500-8. PubMed ID: 16678551
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients.
    Derosa G, Cicero AF, Murdolo G, Piccinni MN, Fogari E, Bertone G, Ciccarelli L, Fogari R.
    Diabetes Obes Metab; 2005 Jan 05; 7(1):47-55. PubMed ID: 15642075
    [Abstract] [Full Text] [Related]

  • 7. Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study.
    Scholze J, Grimm E, Herrmann D, Unger T, Kintscher U.
    Circulation; 2007 Apr 17; 115(15):1991-8. PubMed ID: 17404163
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Blood pressure changes associated with sibutramine and weight management - an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT).
    Sharma AM, Caterson ID, Coutinho W, Finer N, Van Gaal L, Maggioni AP, Torp-Pedersen C, Bacher HP, Shepherd GM, James WP, SCOUT Investigators.
    Diabetes Obes Metab; 2009 Mar 17; 11(3):239-50. PubMed ID: 18671798
    [Abstract] [Full Text] [Related]

  • 10. Randomized, double-blind, placebo-controlled, multicenter study of sibutramine in obese hypertensive patients.
    Hazenberg BP.
    Cardiology; 2000 Mar 17; 94(3):152-8. PubMed ID: 11279320
    [Abstract] [Full Text] [Related]

  • 11. Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients.
    Faria AN, Ribeiro Filho FF, Kohlmann NE, Gouvea Ferreira SR, Zanella MT.
    Diabetes Obes Metab; 2005 May 17; 7(3):246-53. PubMed ID: 15811141
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double-blind, placebo-controlled study.
    Daniels SR, Long B, Crow S, Styne D, Sothern M, Vargas-Rodriguez I, Harris L, Walch J, Jasinsky O, Cwik K, Hewkin A, Blakesley V, Sibutramine Adolescent Study Group.
    Pediatrics; 2007 Jul 17; 120(1):e147-57. PubMed ID: 17576783
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Second phase of a double-blind study clinical trial on Sibutramine for the treatment of patients suffering essential obesity: 6 months after treatment cross-over.
    Fanghänel G, Cortinas L, Sánchez-Reyes L, Berber A.
    Int J Obes Relat Metab Disord; 2001 May 17; 25(5):741-7. PubMed ID: 11360159
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.